Last Saturday, April 6 2013, The CCFA CT Chapter hosted their Annual Patient Education Symposium.
The CCFA CT Chapter is always trying to reach more patients and professional through innovative and new programming via the Web, Print and in Person.
The goal of the event was to help IBD patients become more informed about Nutrition, Medical & Surgical Care, Diagnosis, Complications and New Treatments.
The event was held in Rocky Hill, CT between 8:00AM and 12:00PM.
One of the sessions, Novel Therapies in IBD, was presented by Dr. Phil Ginsberg and Dr. Ioannis Oikonomou. Dr. Oikonomou is a memberof The Inflammatory Bowel Disease Program at Yale UniversitySchool of Medicine.
During his session, Dr. Oikonomou presented promising new therapies that are available through the Yale IBD Program clinical trials research program. Among others, he discussed Ustekinumab - an IL12/23 monoclonal antibody therapy for Crohn’s disease which is already FDA approved for the treatment of psoriasis. Crohn’s and psoriasis are both immune-mediated diseases. Another clinical trial therapy discusses wasTofacitinib - a Janus kinase (JAK) inhibitor - for ulcerative colitis; this is already FDA approved for the treatment of Rheumatoid Arthritis.
Based on his experience with his patients and various clinical trials, Dr. Oikonomou is “ confident that we will be able to offer alternative medications in the near future to patients who do not respond or cannot tolerate current medications.”